Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Nov 06 | 2020No FDA Updates for Liso-cel or Ide-cel; New GPRC5D CAR-T in MM; BMS Q3 2020 Earnings Call SummaryAccess Free BlastFree
Posted in: Allogeneic, BCMA, CAR-T, CD19 Nov 05 | 2020ALLO-715 Ph1 UNIVERSAL Initial Data to be Presented at ASH 2020; Redosing Strategy Confirmed for ALLO-501 Ph1 ALPHA Trial; Allogene Q3 2020 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Oct 30 | 2020Kymriah’s First Asian Commercial Manufacturing Facility is Approved; Novartis Increases Manufacturing Footprint to Five Global CentersAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Oct 29 | 2020Yescarta Sales Impacted by COVID-19; ZUMA-7 Data Delayed to H1 2021; Q3 2020 Gilead Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Oct 27 | 2020Continued Kymriah Sales Growth Despite COVID-19; Kymriah’s LCM Initiatives Remain on Track; Q3 2020 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Oct 25 | 2020Thoughts on Cilta-cel's Global Market Opportunities; Legend and JNJ’s Strategy to Position Cilta-cel in Earlier Lines of Therapy; Legend at Jefferies Cell Therapy Summit Call SummaryAccess Free BlastFree
Posted in: CAR-T Oct 23 | 2020Gilead Appoints Anthony Welters to Their Science Board of DirectorsAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T, CD19, TCR Oct 22 | 2020Thoughts on Ziopharm's TCR-T Programs; Ziopharm at Jefferies Cell Therapy Summit Call SummaryAccess Free BlastFree
Posted in: Allogeneic, CAR-T Oct 16 | 2020Allogene and MD Anderson Announce a 5-Year Collaboration to Develop Allogeneic CAR-TsAccess Free BlastFree
Posted in: CAR-T, CD19 Oct 16 | 2020CHMP Adopts Positive Opinion for Gilead’s Tecartus in r/r Mantle Cell LymphomaAccess Free BlastFree
Posted in: Autologous, CD19 Oct 16 | 2020Thoughts on Ide-cel Data Presentation at ASH 2020; FDA Unlikely to Hold an Ide-cel Advisory Committee Meeting; Summary of bluebird at Jefferies Cell Therapy SummitAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T Oct 15 | 2020Precision BioSciences Wins Patent Challenge Relating to CAR-T EngineeringAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Oct 14 | 2020JNJ-4528 US Filing Anticipated in Q4 2020; JNJ Q3 2020 Earnings SummaryAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T, CD19, TCR Oct 13 | 2020Ziopharm´s RPM Allogeneic CD19 CAR-T Trial Started Enrollment; Q2 2020 Earnings SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Oct 09 | 2020Thoughts on Gilead's sBLA Submission for Yescarta in r/r iNHL (ZUMA-5)Access Free BlastFree
Posted in: Allogeneic, BCMA, CAR-T, CD19 Oct 02 | 2020Precision Biosciences Highlights First Patient Dosed with BCMA CAR-T PBCAR269A; PBCAR0191 Clinical Updates Delayed to YE; Q2 2020 Earnings SummaryAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Sep 30 | 2020Legend Biotech Highlights FDA Filing of Cilta-Cel by YE 2020; Q2 2020 Earnings SummaryAccess Free BlastFree
Posted in: Autologous, BCMA Sep 22 | 2020BMS and bluebird bio Receive Priority Review for Ide-cel; PDUFA Projected Around March 27, 2021Access Free BlastFree
Posted in: Autologous, CD19, CD22 Sep 21 | 2020Updated AUTO3 Ph1/2 ALEXANDER Results; ESMO 2020 Investor Call SummaryAccess Free BlastFree
Posted in: CAR-T, CD123, CD22, CS1 Sep 18 | 2020Thoughts on Cellectis’s CAR-T Program; Potential UCARTCS1 Protocol Changes; Q2 2020 Earnings CallAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.